NEUMORA THERAPEUTICS, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 9.46 USD | +3.39% |
|
-9.13% | -44.52% |
| Apr. 15 | Sector Update: Health Care Stocks Advance Premarket Monday | MT |
| Apr. 15 | Sector Update: Health Care | MT |
Financials (USD)
| Sales 2024 * | - | Sales 2025 * | - | Capitalization | 1.46B |
|---|---|---|---|---|---|
| Net income 2024 * | -237M | Net income 2025 * | -271M | EV / Sales 2024 * | - |
| Net cash position 2024 * | 460M | Net cash position 2025 * | 670M | EV / Sales 2025 * | - |
| P/E ratio 2024 * |
-6.06
x | P/E ratio 2025 * |
-5.77
x | Employees | 124 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 71.3% |
More Fundamentals
* Assessed data
More news
More recommendations
More press releases
| 1 day | +3.39% | ||
| 1 week | -9.13% | ||
| Current month | -31.20% | ||
| 1 month | -31.20% | ||
| 3 months | -39.71% | ||
| 6 months | -18.94% | ||
| Current year | -44.52% |
1 week
8.82
10.47
1 month
8.8214.95
Current year
8.8221.00
1 year
8.8221.00
3 years
8.8221.00
5 years
8.8221.00
10 years
8.8221.00
| Managers | Title | Age | Since |
|---|---|---|---|
Carol Suh
FOU | Founder | 33 | 19-10-31 |
Henry Gosebruch
CEO | Chief Executive Officer | 51 | 23-07-17 |
Paul Berns
FOU | Founder | 57 | 19-10-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Paul Berns
FOU | Founder | 57 | 19-10-31 |
May Kin Ho
BRD | Director/Board Member | 71 | 21-03-31 |
Kristina Burow
BRD | Director/Board Member | 50 | 19-12-31 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-29 | 9.46 | +3.39% | 410,783 |
| 24-04-26 | 9.15 | +0.99% | 677,291 |
| 24-04-25 | 9.06 | -5.53% | 804,136 |
| 24-04-24 | 9.59 | -6.89% | 598,717 |
| 24-04-23 | 10.3 | -1.06% | 328,683 |
Delayed Quote Nasdaq, April 29, 2024 at 04:00 pm EDT
More quotes
Neumora Therapeutics Inc. is a clinical-stage biopharmaceutical company. The Companyâs therapeutic pipeline consists of seven clinical and preclinical neuroscience programs that target novel mechanisms of action for a broad range of underserved neuropsychiatric disorders and neurodegenerative diseases. Its advanced product candidate, navacaprant (NMRA-140), is a novel once-daily oral kappa opioid receptor (KOR) antagonist that is being developed for the treatment of depressive disorder (MDD). Its other candidates include NMRA-266, NMRA-511, and NMRA-NMDA. NMRA-266 is a positive allosteric modulator program of the M4 muscarinic receptor (M4R) for the treatment of schizophrenia. NMRA-266 is designed to be selective for the M4 receptor subtype of the muscarinic receptor family. NMRA-511 is an investigational antagonist of the vasopressin 1a receptor (V1aR). NMRA-NMDA is an NMDA positive allosteric modulator program that the Company is developing for the treatment of schizophrenia.
Calendar
Related indices
Sell
Buy
Mean consensus
BUY
Number of Analysts
6
Last Close Price
9.15
USD
Average target price
24.71
USD
Spread / Average Target
+170.07%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -44.52% | 1.46B | |
| +1.77% | 42.75B | |
| +47.70% | 41.61B | |
| +12.24% | 41.34B | |
| -8.83% | 26.59B | |
| +7.44% | 25.49B | |
| -23.01% | 18.12B | |
| +30.56% | 12.24B | |
| -1.82% | 11.76B | |
| +8.35% | 11B |
- Stock Market
- Equities
- NMRA Stock
